Novartis (VTX:NOVN) PT Set at CHF 82 by JPMorgan Chase & Co.

JPMorgan Chase & Co. set a CHF 82 target price on Novartis (VTX:NOVN) in a report published on Tuesday morning, Borsen Zeitung reports. The firm currently has a sell rating on the stock.

A number of other analysts have also recently weighed in on NOVN. Goldman Sachs Group set a CHF 105 price target on shares of Novartis and gave the company a buy rating in a report on Monday, July 29th. HSBC set a CHF 88 price objective on shares of Novartis and gave the company a neutral rating in a research report on Monday, July 22nd. Barclays set a CHF 80 price objective on shares of Novartis and gave the company a sell rating in a research report on Friday, July 19th. Jefferies Financial Group set a CHF 95 price objective on shares of Novartis and gave the company a buy rating in a research report on Thursday, May 16th. Finally, Deutsche Bank set a CHF 90 price objective on shares of Novartis and gave the company a neutral rating in a research report on Friday, July 19th. Three research analysts have rated the stock with a sell rating, five have given a hold rating and six have assigned a buy rating to the stock. The company has a consensus rating of Hold and an average target price of CHF 89.71.

Novartis has a 1-year low of CHF 72.45 and a 1-year high of CHF 88.30.

Novartis Company Profile

Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.

Read More: Buy Rating

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.